Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
Open Access
- 5 June 2023
- journal article
- research article
- Published by Springer Nature in npj Vaccines
- Vol. 8 (1) , 1-9
Abstract
Distribution of vaccines which require refrigerated or frozen storage can be challenging and expensive. The adenovirus vector platform has been widely used for COVID-19 vaccines while several further candidate vaccines using the platform are in clinical development. In current liquid formulations, adenoviruses require distribution at 2–8 °C. The development of formulations suitable for ambient temperature distribution would be advantageous. Previous peer-reviewed reports of adenovirus lyophilization are relatively limited. Here, we report the development of a formulation and process for lyophilization of simian adenovirus-vectored vaccines based on the ChAdOx1 platform. We describe the iterative selection of excipients using a design of experiments approach, and iterative cycle improvement to achieve both preservation of potency and satisfactory cake appearance. The resulting method achieved in-process infectivity titre loss of around 50%. After drying, there was negligible further loss over a month at 30 °C. Around 30% of the predrying infectivity remained after a month at 45 °C. This performance is likely to be suitable for ‘last leg’ distribution at ambient temperature. This work may also facilitate the development of other product presentations using dried simian adenovirus-vectored vaccines.Keywords
Funding Information
- RCUK | Engineering and Physical Sciences Research Council (EP/R013756/1, EP/R013756/1, EP/R013756/1, EP/R013756/1, EP/R013756/1, EP/N025105/1, EP/M028100/1)
- RCUK | Medical Research Council (MR/P017339)
- Wellcome Trust (220679/Z/20/Z)
This publication has 24 references indexed in Scilit:
- Use of adenovirus as a model system to illustrate a simple method using standard equipment and inexpensive excipients to remove live virus dependence on the cold-chainVaccine, 2014
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative ImmunogenicityPLOS ONE, 2012
- Investigation on formulation and preparation of adenovirus encoding human endostatin lyophilized powdersInternational Journal of Pharmaceutics, 2012
- Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple SpeciesScience Translational Medicine, 2012
- Freeze drying formulation using microscale and design of experiment approaches: a case study using granulocyte colony-stimulating factorBiotechnology Letters, 2011
- Rapid optimization of protein freeze‐drying formulations using ultra scale‐down and factorial design of experiment in microplatesBiotechnology and Bioengineering, 2009
- Development of stable liquid formulations for adenovirus-based vaccinesJournal of Pharmaceutical Sciences, 2004
- Freeze‐Drying of Mannitol–Trehalose–Sodium Chloride‐Based Formulations: The Impact of Annealing on Dry Layer Resistance to Mass Transfer and Cake StructurePharmaceutical Development and Technology, 2004
- Development of formulations that enhance physical stability of viral vectors for gene therapyGene Therapy, 2001
- Development of Novel Formulations That Enhance Adenoviral-Mediated Gene Expression in the Lung in Vitro and in VivoMolecular Therapy, 2001